

Eva M Putz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7176547/publications.pdf>

Version: 2024-02-01

41
papers

1,878
citations

279487

23
h-index

414034

32
g-index

43
all docs

43
docs citations

43
times ranked

3580
citing authors

#	ARTICLE	IF	CITATIONS
1	CIS is a potent checkpoint in NK cell-mediated tumor immunity. <i>Nature Immunology</i> , 2016, 17, 816-824.	7.0	289
2	Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment. <i>Cancer Cell</i> , 2018, 33, 634-648.e5.	7.7	163
3	Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. <i>Blood</i> , 2018, 132, 694-706.	0.6	132
4	STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion. <i>Cancer Discovery</i> , 2016, 6, 414-429.	7.7	124
5	JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation. <i>Frontiers in Immunology</i> , 2019, 10, 2590.	2.2	110
6	CDK8-Mediated STAT1-S727 Phosphorylation Restrains NK Cell Cytotoxicity and Tumor Surveillance. <i>Cell Reports</i> , 2013, 4, 437-444.	2.9	104
7	Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis. <i>Cancer Immunology Research</i> , 2017, 5, 1098-1108.	1.6	98
8	Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. <i>Blood</i> , 2014, 124, 2370-2379.	0.6	90
9	NK cell heparanase controls tumor invasion and immune surveillance. <i>Journal of Clinical Investigation</i> , 2017, 127, 2777-2788.	3.9	85
10	Bench to bedside: NK cells and control of metastasis. <i>Clinical Immunology</i> , 2017, 177, 50-59.	1.4	71
11	PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis. <i>Leukemia</i> , 2014, 28, 629-641.	3.3	56
12	Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. <i>Oncot Immunology</i> , 2012, 1, 1027-1037.	2.1	53
13	Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis. <i>Oncot Immunology</i> , 2017, 6, e1267892.	2.1	53
14	Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function. <i>Nature Communications</i> , 2020, 11, 4166.	5.8	53
15	Leukemic challenge unmasks a requirement for PI3K γ in NK cell-mediated tumor surveillance. <i>Blood</i> , 2008, 112, 4655-4664.	0.6	48
16	NK Cell-Specific CDK8 Deletion Enhances Antitumor Responses. <i>Cancer Immunology Research</i> , 2018, 6, 458-466.	1.6	40
17	In Vivo Long-Term Kinetics of Radiolabeled N,N-Dimethyltryptamine and Tryptamine. <i>Journal of Nuclear Medicine</i> , 2011, 52, 970-977.	2.8	32
18	The cooperating mutation or second hit determines the immunologic visibility toward MYC-induced murine lymphomas. <i>Blood</i> , 2011, 118, 4635-4645.	0.6	30

#	ARTICLE	IF	CITATIONS
19	PI3K \hat{I} Is Essential for Tumor Clearance Mediated by Cytotoxic T Lymphocytes. <i>PLoS ONE</i> , 2012, 7, e40852.	1.1	30
20	Identification of an Indispensable Role for Tyrosine Kinase 2 in CTL-Mediated Tumor Surveillance. <i>Cancer Research</i> , 2009, 69, 203-211.	0.4	29
21	In vivotumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity. <i>Oncolmmunology</i> , 2015, 4, e1047579.	2.1	27
22	Targeting VEGF-A in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia. <i>Nature Communications</i> , 2016, 7, 12528.	5.8	25
23	CD52 is a molecular target in advanced systemic mastocytosis. <i>FASEB Journal</i> , 2014, 28, 3540-3551.	0.2	24
24	Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice. <i>Oncolmmunology</i> , 2015, 4, e998529.	2.1	24
25	The Tyrosine Kinase Btk Regulates the Macrophage Response to <i>Listeria monocytogenes</i> Infection. <i>PLoS ONE</i> , 2013, 8, e60476.	1.1	18
26	NK cell development in bone marrow and liver: site matters. <i>Genes and Immunity</i> , 2014, 15, 584-587.	2.2	15
27	Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance. <i>Cancers</i> , 2014, 6, 193-210.	1.7	13
28	Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity. <i>Oncolmmunology</i> , 2016, 5, e1186314.	2.1	13
29	STAT1-S727 - the license to kill. <i>Oncolmmunology</i> , 2014, 3, e955441.	2.1	9
30	Loss of NKG2D in murine NK cells leads to increased perforin production upon long-term stimulation with IL-2. <i>European Journal of Immunology</i> , 2020, 50, 880-890.	1.6	9
31	Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study. <i>Oral Oncology</i> , 2022, 124, 105634.	0.8	9
32	Bcl-2. <i>Oncolmmunology</i> , 2012, 1, 749-750.	2.1	2
33	STAT1 Ser727 is a key regulator for NK cell-mediated cytotoxicity and tumor surveillance. <i>BMC Pharmacology</i> , 2008, 8, .	0.4	0
34	Unexpected role of STAT1 serine727 for NK cell function. <i>BMC Pharmacology</i> , 2009, 9, .	0.4	0
35	PS2-084 Dissection of kinase-dependent and -independent functions of Tyk2 in immunity to infection and tumor-surveillance. <i>Cytokine</i> , 2011, 56, 86.	1.4	0
36	PI3K \hat{I} is indispensable for CTL-mediated cytotoxicity. <i>BMC Pharmacology</i> , 2011, 11, .	0.4	0

#	ARTICLE	IF	CITATIONS
37	STAT Transcription Factors: Controlling All Aspects of NK Cell Biology. , 2012, , 187-204.		0
38	Targeting PI3K \hat{I} . Oncoimmunology, 2013, 2, e22272.	2.1	0
39	ID: 77. Cytokine, 2015, 76, 79.	1.4	0
40	CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Intrinsic Activity, 2013, 1, A3.4.	0.0	0
41	Abstract IA27: Novel natural killer cell targets for cancer immunotherapy. , 2016, , .		0